---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-021916"
form_type: "8-K"
ticker: "SILO"
cik: "0001514183"
company_name: "Silo Pharma, Inc."
filed_at: "2025-03-10T23:59:59+00:00"
generated_at: "2026-05-25T01:21:06.786950+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Silo Pharma provides pipeline update; pre-IND for SPC-15 pending FDA guidance

## Summary
- Lead asset SPC-15 (intranasal PTSD treatment) aims for first-in-human trials after FDA pre-IND feedback.
- Exclusive global licenses from Columbia University for SPC-15 and SPC-14 (Alzheimer's).
- SP-26 (ketamine implant for fibromyalgia) March 2025 data expected; 505(b)(2) pathway planned.
- SPC-14 (Alzheimer's) and SPU-16 (multiple sclerosis) in preclinical with 2025 data targets.
- Company states sufficient capital resources and no debt to support upcoming catalysts.

## SEC filing metadata
- accession: 0001213900-25-021916
- form_type: 8-K
- ticker: SILO
- cik: 0001514183
- company_name: Silo Pharma, Inc.
- filed_at: 2025-03-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1514183/000121390025021916/0001213900-25-021916-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1514183/000121390025021916/ea0233727-8k_silopharma.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-021916
- JSON: https://secwatch.observer/filing/0001213900-25-021916.json
- Plain text: https://secwatch.observer/filing/0001213900-25-021916.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.